This week the headline appeared to have some tough news for RNA companies, but Alnylam remains undeterred about the potential of its treatments.» Read More
European shares closed lower on Thursday with investor confidence curbed by a mixed bag of earnings from major companies and concerns about slowing growth in China.
Daniel O'Day, CEO of Roche, talks about the company's results for the first half of the year and sales of its new breast cancer drugs.
Daniel O'Day, CEO of Roche's pharma unit, declines to comment on Alexion deal talks, but says the company is keen on incorporating innovations into its portfolio.
Daniel O'Day, the CEO of Roche's pharmaceuticals unit declined to comment on market rumors that the Swiss drug maker is about to bid for Alexion, but told CNBC that the company continues to look for new innovations.
Andrew Weiss, head of pharma and biotech research at Vontobel, , talks about Novartis' quarterly results and outlook and says the company will remain under pressure for the next few quarters.
Pharmaceutical and biotech stocks have outperformed markets this year, and with J&J's second-quarter earnings beat, investors may hope earnings will push stocks even higher.
Some of the names on the move ahead of the open.
Amgen's low-ball offer to Onyx Pharmaceuticals has set off speculation of a potential bidding war that could leave another company walking away with Onyx.
Bristol-Myers Squibb and Merck stocks climbed higher Monday as analysts said billions stood to be made from treatment breakthroughs.
Hal Barron, Roche/Genentech chief medical officer, shares several new developments in treating cancer, including some promising results with Roche/Genentech 's Avastin.
The spotlight at this year's American Society of Clinical Oncologists meeting will be on data from Bristol-Myers Squibb, Roche, and Merck on a new class of cancer drugs.
European shares were higher in early afternoon trade on Wednesday despite preliminary growth data from the euro zone missing estimates.
European shares closed sharply higher on Tuesday after a positive Spanish bond auction and better-than-expected French manufacturing data buoyed investor sentiment.
Genetic testing equipment maker Life Technologies has agreed to a $13.6 billion cash buyout by Thermo Fisher Scientific, in one of the year's biggest corporate takeovers.
European shares closed higher on Thursday after better-than-expected initial jobless claims data from the U.S. The numbers are important as a key metric for Fed policy makers, who have said they could taper off asset purchases once the labor market improves.
Daniel O'Day, head of pharmaceutical operations at Roche, tells CNBC that the company haven't seen a huge effect from the Sequester in the US.
Andrew Weiss, head of Pharma at Vontobel, tells CNBC that Roche delivered earnings in line with expectations.
China said it was mobilizing resources nationwide to combat a new strain of bird flu that has killed six people, as Japan, Hong Kong and the United States stepped up vigilance.
At least three companies are on the cutting edge of new treatments for perhaps the most feared disease known to mankind.
China has found two more cases of a new strain of bird flu and one of the victims has died, bringing to nine the number of confirmed human infections from the previously unknown flu type.